Japan-based Mitsubishi Chemical Group has decided to cease all of its operations at Medicago Inc., a Canadian subs...
New South Wales (NSW) in Australia is further expanding free access to Japanese encephalitis (JE) vaccine to ensure resi...
The International Vaccine Institute (IVI), based in Seoul (South Korea) has launched an IVI Country Office in&...
Genexine, a clinical-staged Korean biopharmaceutical company committed to the discovery and development of novel biologi...
US-based Novavax, Inc. has announced that partner SK bioscience, based in South Korea, has received expanded manufacturi...
In a historic move in the global fight against the COVID-19 pandemic, the United Arab Emirates (UAE) has announced the c...
Gachon University, the Korea mRNA Vaccine Initiative (KmVAC), and the International Vaccine Institute (IVI) recently exc...
South Korea headquatered SK bioscience, a global innovative vaccine and biotech company, has received a biologics licens...
The University of Queensland (UQ) team has become the biggest supplier of experimental mRNA vaccines and therapies ...
The International Vaccine Institute (IVI), a South Korea-based international organisation devoted to vaccines for global...
On December 2nd, a nasal spray COVID-19 vaccine, VectorFlu ONE, was approved for emergency use (EU) by the national auth...
Bio Farma, Holding SOE Pharmacy – with its subsidiaries Kimia Farma and Indofarma, has signed a framework agreemen...
Chinese biotech startup Stemirna Therapeutics has received an Emergency Use Authorisation (EUA) from the FDA for ...
Malaysia's Pharmaniaga LifeScience Sdn Bhd (PLS) and Pharmaniaga Berhad have signed a Research Collaboration Agreem...
Moderna, Inc., has announced its Singapore subsidiary with a new leadership announcement. Evelyn Pang has been ap...
Japanese pharmaceutical firm Takeda has announced that the European Commission (EC) has granted marketing authorisation ...
Norway-based Coalition for Epidemic Preparedness Innovations (CEPI) is expanding its world-leading portfolio of potentia...
Vaxxas has completed a financing round which raised $23 million (A$34 million) in new funds. This investment round was l...
